Spruce Biosciences, Inc. IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Spruce Biosciences, Inc., and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Spruce Biosciences, Inc. | SPRB - NASDAQ |
$14.00-$16.00 | $15.00 | $18.14 | 6 million | 10/9/2020 |
| Cowen, SVB Leerink, Credit Suisse, RBC Capital | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-09-18 Terms Added 2020-10-05 | ||||||
Spruce Biosciences, Inc. Quote & Chart - Click for current quote - SPRB
IPO Boutique aggregates information on public companies and private companies, such as "SPRB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Spruce Biosciences, Inc. (adapted from Spruce Biosciences, Inc. prospectus):
They are a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "SPRB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.